Bone marrow MicroRNA-335 level predicts the chemotherapy response and prognosis of adult acute myeloid leukemia

Medicine (United States)

Volumn 94, Issue 33, 2015, Pages e986-

  Yingchun, Li ^a   Rong, Zhang ^a   Kun, Yao ^a   Ying, Yang ^a   Zhuogang, Liu ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTARABINE; DAUNORUBICIN; HOMOHARRINGTONINE; MICRORNA; MICRORNA 335; MITOXANTRONE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; MIRN335 MICRORNA, HUMAN;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ACUTE MONOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ADULT; ARTICLE; BLOOD LEVEL; BONE MARROW; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; DIAGNOSTIC TEST ACCURACY STUDY; ERYTHROLEUKEMIA; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TREATMENT RESPONSE; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; PROCEDURES; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CYTARABINE; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84943147109     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000986     Document Type: Article

References (30)

1. Bienz M, Ludwig M, Leibundgut EO, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res. 2005; 11: 1416-1424
2. Tallman MS. New agents for the treatment of acute myeloid leukemia. Best Pract Res Clin Haematol. 2006; 19: 311-320
3. Cornelissen JJ, Lowenberg B. Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2005[pii]10.1182/asheducation-2005.1.151151-155
4. Greenwood MJ, Seftel MD, Richardson C, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma. 2006; 47: 1245-1252
5. Sharawat SK, Gupta R, Raina V, et al. Increased coexpression of c-KIT and FLT3 receptors on myeloblasts: independent predictor of poor outcome in pediatric acute myeloid leukemia. Cytometry B Clin Cytom. 2013; 84: 390-397
6. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999; 94: 3717-3721
7. Zhu HH, Liu YR, Jiang H, et al. CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation. Leuk Res. 2013; 37: 624-630
8. Zhang H, Li Y, Lai M. The microRNA network and tumor metastasis. Oncogene. 2010; 29: 937-948
9. Gao Y, Zeng F, Wu JY, et al. MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met. Tumour Biol. 201410.1007/s13277-014-2917-6
10. Li Z, Li D, Zhang G, et al. Methylation-Associated silencing of MicroRNA-335 contributes tumor cell invasion and migration by interacting with RASA1 in gastric cancer. Am J Cancer Res. 2014; 4: 648-662
11. Zhang BJ, Gong HY, Zheng F, et al. Up-regulation of miR-335 predicts a favorable prognosis in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2014; 7: 6213-6218
12. Lin X, Wang Z, Zhang R, et al. High serum microRNA-335 level predicts aggressive tumor progression and unfavorable prognosis in pediatric acute myeloid leukemia. Clin Transl Oncol. 201410.1007/s12094-014-1237-z.
13. Zhang H, Luo XQ, Zhang P, et al. MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One. 2009; 4: e7826
14. Xu PP, Chen BA, Feng JF, et al. Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia. Chin Med J (Engl). 2012; 125: 2137-2143
15. Buccisano F, Maurillo L, Spagnoli A, et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood. 2010; 116: 2295-2303
16. Bai J, Guo A, Hong Z, et al. Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia. Onco Targets Ther. 2012; 5: 213-219
17. Marcucci G, Mrozek K, Radmacher MD, et al. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood. 2011; 117: 1121-1129
18. Marcucci G, Maharry K, Radmacher MD, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol. 2008; 26: 5078-5087
19. Schwind S, Maharry K, Radmacher MD, et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010; 28: 5257-5264
20. Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358: 1919-1928
21. van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med. 2014; 6: 851-864
22. Yang D, Lutter D, Burtscher I, et al. miR-335 promotes mesendodermal lineage segregation and shapes a transcription factor gradient in the endoderm. Development. 2014; 141: 514-525
23. Tome M, Lopez-Romero P, Albo C, et al. miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. Cell Death Differ. 2011; 18: 985-995
24. Heyn H, Engelmann M, Schreek S. MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development. Int J Cancer. 2011; 129: 2797-2806
25. Gong M, Ma J, Guillemette R, et al. miR-335 inhibits small cell lung cancer bone metastases via IGF-IR and RANKL pathways. Mol Cancer Res. 2014; 12: 101-110
26. Shu M, Zheng X, Wu S, et al. Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells. Mol Cancer. 2011; 10: 59
27. Manchanda PK, Jones GN, Lee AA, et al. Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors. Oncogene. 2013; 32: 3491-3499
28. Yan Z, Xiong Y, Xu W, et al. Identification of hsa-miR-335 as a prognostic signature in gastric cancer. PLoS One. 2012; 7: e40037
29. Hou X, Zeng H, He X, et al. Sirt3 is essential for apelin-induced angiogenesis in post-myocardial infarction of diabetes. J Cell Mol Med. 2015; 19: 53-61
30. Hou X, Hu Z, Xu H, et al. Advanced glycation endproducts trigger autophagy in cadiomyocyte via RAGE/PI3K/AKT/mTOR pathway. Cardiovasc Diabetol. 2014; 13: 78